Format

Send to

Choose Destination
Drug Discov Today. 2014 Aug;19(8):1033-9. doi: 10.1016/j.drudis.2014.03.018. Epub 2014 Mar 26.

An overview of FDA-approved new molecular entities: 1827-2013.

Author information

1
Yale Center for Molecular Discovery, Yale University, 600 West Campus Drive, West Haven, CT 06516, USA. Electronic address: michael.kinch@yale.edu.
2
Yale Center for Molecular Discovery, Yale University, 600 West Campus Drive, West Haven, CT 06516, USA.

Abstract

The pharmaceutical industry is undergoing fundamental change and its future is unclear. We performed a meta-analysis by cataloging FDA-approved legacy drugs and new molecular entities (NMEs). Objective information regarding scientific, medical and commercial activities was captured and provides insight into processes governing drug development. In this report, we review the rates of NME introduction through to the end of 2013. Recent trends show the emergence of a handful of companies that controls two-thirds of NMEs. We also report growth in the number of NMEs controlled by marketing organizations that have little or no internal drug discovery or development activities. This trend has increased dramatically since 2000 and could raise important questions about the future landscape and viability of drug discovery and development.

PMID:
24680947
DOI:
10.1016/j.drudis.2014.03.018
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center